The global Nectin-4-Directed Antibody Drug Conjugates (ADC) market was valued at US$ 1785 million in 2025 and is anticipated to reach US$ 3340 million by 2032, at a CAGR of 9.3% from 2026 to 2032.

Nectin-4-Directed Antibody Drug Conjugates (ADC) Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Nectin-4-Directed Antibody Drug Conjugates (ADC) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

In 2025, global Nectin-4-Directed Antibody Drug Conjugates (ADC) production reached approximately 961 K Units, with an average global market price of around 1857 USD per Unit.

Nectin-4–directed antibody–drug conjugates (ADCs) are targeted cancer therapies in which a monoclonal antibody that specifically binds the cell-surface protein Nectin-4 (PVRL4) is chemically linked (via a linker) to a cytotoxic payload. After the antibody binds Nectin-4 on tumor cells, the ADC is typically internalized, the linker is cleaved (or the antibody is degraded), and the payload is released inside the cell to kill the cancer cell .

Nectin-4–directed antibody–drug conjugates (ADCs) stand out because they combine a clinically validated tumor-associated target with the precision of antibody binding and the potency of a cytotoxic payload, addressing one of oncology’s most persistent pain points: how to deliver strong cell-killing therapy while limiting the broad, systemic damage seen with traditional chemotherapy. By exploiting Nectin-4 expression on certain epithelial tumors, these ADCs can concentrate drug exposure in malignant tissue, potentially improving the therapeutic window, enabling meaningful activity in patients who have exhausted standard options, and creating room for rational combinations that deepen and extend responses without simply escalating toxicity. The industry tailwinds are strong: continued demand for differentiated, high-value oncology assets; rapid maturation of linker and payload technologies that can fine-tune efficacy and tolerability; growing confidence from regulators and clinicians as ADC know-how improves; and a clear commercial incentive to develop targeted therapies that fit biomarker-driven treatment pathways and expand into earlier lines of therapy. Looking ahead, the Nectin-4 ADC space is evolving from a single-product story into a competitive innovation arena where next-generation designs aim to improve safety profiles, broaden eligible patient populations, and prove durability across additional tumor types, making it a compelling segment of the broader ADC market with credible momentum and a runway for sustained growth as clinical experience, manufacturing scale, and combination strategies continue to mature.

The upstream raw materials for Nectin-4-Directed Antibody Drug Conjugates (ADCs) mainly include antibodies, payloads, linkers, etc. Typical suppliers include Thermo Fisher, Merck, WuXi XDC, Porton, etc. The downstream applications are mainly in the treatment of diseases such as urothelial carcinoma, esophageal cancer, and triple-negative breast cancer.

The production capacity of Nectin-4-Directed Antibody Drug Conjugates (ADCs) varies greatly depending on the scale of antibody expression, the level of conjugation technology, and the formulation filling capacity. The gross profit margin of Nectin-4-Directed Antibody Drug Conjugates (ADCs) is in the range of 70%-80%.

The North American market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC) include Astellas, Innate Pharma, Corbus Pharmaceuticals, BioAtla, Eli Lilly, Adcentrx Therapeutics, Mabwell, Jiangsu Hengrui, Cspc Holdings, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Nectin-4-Directed Antibody Drug Conjugates (ADC) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nectin-4-Directed Antibody Drug Conjugates (ADC). The Nectin-4-Directed Antibody Drug Conjugates (ADC) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Nectin-4-Directed Antibody Drug Conjugates (ADC) market comprehensively. Regional market sizes by Type, by Application, by Payload Mechanism, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Nectin-4-Directed Antibody Drug Conjugates (ADC) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Report

Report Metric	Details
Report Name	Nectin-4-Directed Antibody Drug Conjugates (ADC) Market
Accounted market size in 2025	US$ 1785 million
Forecasted market size in 2032	US$ 3340 million
CAGR	9.3%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Cleavable Linkers Non-cleavable Linkers
Segment by Payload Mechanism	Microtubule inhibitors Topoisomerase Inhibitor Others
Segment by Antibody	Humanized IgG1 Fc Silencing IgG1
by Application	Bladder Cancer Esophageal Cancer Triple-negative Breast Cancer Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Astellas, Innate Pharma, Corbus Pharmaceuticals, BioAtla, Eli Lilly, Adcentrx Therapeutics, Mabwell, Jiangsu Hengrui, Cspc Holdings
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Payload Mechanism, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Nectin-4-Directed Antibody Drug Conjugates (ADC) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Nectin-4-Directed Antibody Drug Conjugates (ADC) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Nectin-4-Directed Antibody Drug Conjugates (ADC) Market growing?

Ans: The Nectin-4-Directed Antibody Drug Conjugates (ADC) Market witnessing a CAGR of 9.3% during the forecast period 2026-2032.

What is the Nectin-4-Directed Antibody Drug Conjugates (ADC) Market size in 2032?

Ans: The Nectin-4-Directed Antibody Drug Conjugates (ADC) Market size in 2032 will be US$ 3340 million.

Who are the main players in the Nectin-4-Directed Antibody Drug Conjugates (ADC) Market report?

Ans: The main players in the Nectin-4-Directed Antibody Drug Conjugates (ADC) Market are Astellas, Innate Pharma, Corbus Pharmaceuticals, BioAtla, Eli Lilly, Adcentrx Therapeutics, Mabwell, Jiangsu Hengrui, Cspc Holdings

What are the Application segmentation covered in the Nectin-4-Directed Antibody Drug Conjugates (ADC) Market report?

Ans: The Applications covered in the Nectin-4-Directed Antibody Drug Conjugates (ADC) Market report are Bladder Cancer, Esophageal Cancer, Triple-negative Breast Cancer, Others

What are the Type segmentation covered in the Nectin-4-Directed Antibody Drug Conjugates (ADC) Market report?

Ans: The Types covered in the Nectin-4-Directed Antibody Drug Conjugates (ADC) Market report are Cleavable Linkers, Non-cleavable Linkers

1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Overview

1.1 Product Definition

1.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type

1.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type: 2025 vs 2032

1.2.2 Cleavable Linkers

1.2.3 Non-cleavable Linkers

1.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Payload Mechanism

1.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism: 2025 vs 2032

1.3.2 Microtubule inhibitors

1.3.3 Topoisomerase Inhibitor

1.3.4 Others

1.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Antibody

1.4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody: 2025 vs 2032

1.4.2 Humanized IgG1

1.4.3 Fc Silencing IgG1

1.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application

1.5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application: 2025 vs 2032

1.5.2 Bladder Cancer

1.5.3 Esophageal Cancer

1.5.4 Triple-negative Breast Cancer

1.5.5 Others

1.6 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size Estimates and Forecasts

1.6.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021–2032

1.6.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021–2032

1.6.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competition by Manufacturers

2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Manufacturers (2021–2026)

2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Nectin-4-Directed Antibody Drug Conjugates (ADC), Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Product Types and Applications

2.7 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Date of Entry into the Industry

2.8 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competitive Situation and Trends

2.8.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Players Market Share by Revenue

2.8.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Scenario by Region

3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2021–2032

3.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2021–2026

3.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2027–2032

3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021–2032

3.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021–2026

3.3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2027–2032

3.4 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country

3.4.1 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)

3.4.3 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country

3.5.1 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)

3.5.3 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Region

3.6.1 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (2021–2032)

3.6.3 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country

3.7.1 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)

3.7.3 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country

3.8.1 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)

3.8.3 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021–2032)

4.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021–2026)

4.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2027–2032)

4.1.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021–2032)

4.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021–2032)

4.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021–2026)

4.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2027–2032)

4.2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021–2032)

4.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price by Type (2021–2032)

5 Segment by Application

5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021–2032)

5.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021–2026)

5.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2027–2032)

5.1.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021–2032)

5.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021–2032)

5.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021–2026)

5.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2027–2032)

5.2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021–2032)

5.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Astellas

6.1.1 Astellas Company Information

6.1.2 Astellas Description and Business Overview

6.1.3 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.1.5 Astellas Recent Developments/Updates

6.2 Innate Pharma

6.2.1 Innate Pharma Company Information

6.2.2 Innate Pharma Description and Business Overview

6.2.3 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.2.5 Innate Pharma Recent Developments/Updates

6.3 Corbus Pharmaceuticals

6.3.1 Corbus Pharmaceuticals Company Information

6.3.2 Corbus Pharmaceuticals Description and Business Overview

6.3.3 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.3.5 Corbus Pharmaceuticals Recent Developments/Updates

6.4 BioAtla

6.4.1 BioAtla Company Information

6.4.2 BioAtla Description and Business Overview

6.4.3 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.4.5 BioAtla Recent Developments/Updates

6.5 Eli Lilly

6.5.1 Eli Lilly Company Information

6.5.2 Eli Lilly Description and Business Overview

6.5.3 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.5.5 Eli Lilly Recent Developments/Updates

6.6 Adcentrx Therapeutics

6.6.1 Adcentrx Therapeutics Company Information

6.6.2 Adcentrx Therapeutics Description and Business Overview

6.6.3 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.6.5 Adcentrx Therapeutics Recent Developments/Updates

6.7 Mabwell

6.7.1 Mabwell Company Information

6.7.2 Mabwell Description and Business Overview

6.7.3 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.7.5 Mabwell Recent Developments/Updates

6.8 Jiangsu Hengrui

6.8.1 Jiangsu Hengrui Company Information

6.8.2 Jiangsu Hengrui Description and Business Overview

6.8.3 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.8.5 Jiangsu Hengrui Recent Developments/Updates

6.9 Cspc Holdings

6.9.1 Cspc Holdings Company Information

6.9.2 Cspc Holdings Description and Business Overview

6.9.3 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio

6.9.5 Cspc Holdings Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Chain Analysis

7.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Production Mode & Process Analysis

7.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales and Marketing

7.4.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Channels

7.4.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors

7.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) Customer Analysis

8 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Dynamics

8.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Trends

8.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Drivers

8.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Challenges

8.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astellas

Innate Pharma

Corbus Pharmaceuticals

Adcentrx Therapeutics

List of Tables

Table 1. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism (US$ Million), 2025 vs 2032

Table 3. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody (US$ Million), 2025 vs 2032

Table 4. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competitive Situation by Manufacturers in 2025

Table 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) of Key Manufacturers (2021–2026)

Table 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Manufacturers (2021–2026)

Table 8. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of Nectin-4-Directed Antibody Drug Conjugates (ADC), Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Product Types and Applications

Table 14. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2021–2026

Table 20. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021–2026)

Table 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2027–2032

Table 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2027–2032)

Table 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2021–2026

Table 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021–2026)

Table 25. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2027–2032

Table 26. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2027–2032)

Table 27. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026

Table 29. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032

Table 30. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026

Table 31. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032

Table 32. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026

Table 34. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032

Table 35. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026

Table 36. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2021–2026

Table 39. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2027–2032

Table 40. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026

Table 44. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032

Table 45. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026

Table 49. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032

Table 50. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032

Table 52. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Type (2021–2026)

Table 53. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Type (2027–2032)

Table 54. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021–2026)

Table 55. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2027–2032)

Table 56. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Type (2021–2026)

Table 57. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Type (2027–2032)

Table 58. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021–2026)

Table 59. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2027–2032)

Table 60. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2021–2026)

Table 61. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2027–2032)

Table 62. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Application (2021–2026)

Table 63. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Application (2027–2032)

Table 64. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021–2026)

Table 65. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2027–2032)

Table 66. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Application (2021–2026)

Table 67. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Application (2027–2032)

Table 68. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021–2026)

Table 69. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2027–2032)

Table 70. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2021–2026)

Table 71. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2027–2032)

Table 72. Astellas Company Information

Table 73. Astellas Description and Business Overview

Table 74. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 75. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 76. Astellas Recent Developments/Updates

Table 77. Innate Pharma Company Information

Table 78. Innate Pharma Description and Business Overview

Table 79. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 80. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 81. Innate Pharma Recent Developments/Updates

Table 82. Corbus Pharmaceuticals Company Information

Table 83. Corbus Pharmaceuticals Description and Business Overview

Table 84. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 85. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 86. Corbus Pharmaceuticals Recent Developments/Updates

Table 87. BioAtla Company Information

Table 88. BioAtla Description and Business Overview

Table 89. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 90. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 91. BioAtla Recent Developments/Updates

Table 92. Eli Lilly Company Information

Table 93. Eli Lilly Description and Business Overview

Table 94. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 95. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 96. Eli Lilly Recent Developments/Updates

Table 97. Adcentrx Therapeutics Company Information

Table 98. Adcentrx Therapeutics Description and Business Overview

Table 99. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 100. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 101. Adcentrx Therapeutics Recent Developments/Updates

Table 102. Mabwell Company Information

Table 103. Mabwell Description and Business Overview

Table 104. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 105. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 106. Mabwell Recent Developments/Updates

Table 107. Jiangsu Hengrui Company Information

Table 108. Jiangsu Hengrui Description and Business Overview

Table 109. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 110. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 111. Jiangsu Hengrui Recent Developments/Updates

Table 112. Cspc Holdings Company Information

Table 113. Cspc Holdings Description and Business Overview

Table 114. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 115. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product

Table 116. Cspc Holdings Recent Developments/Updates

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors List

Table 120. Nectin-4-Directed Antibody Drug Conjugates (ADC) Customers List

Table 121. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Trends

Table 122. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Drivers

Table 123. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Challenges

Table 124. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Restraints

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Authors List of This Report

List of Figures

Figure 1. Product Picture of Nectin-4-Directed Antibody Drug Conjugates (ADC)

Figure 2. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Type: 2025 & 2032

Figure 4. Cleavable Linkers Product Picture

Figure 5. Non-cleavable Linkers Product Picture

Figure 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism (US$ Million), 2021–2032

Figure 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Payload Mechanism: 2025 vs 2032

Figure 8. Microtubule inhibitors Product Picture

Figure 9. Topoisomerase Inhibitor Product Picture

Figure 10. Others Product Picture

Figure 11. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody (US$ Million), 2021–2032

Figure 12. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Antibody: 2025 vs 2032

Figure 13. Humanized IgG1 Product Picture

Figure 14. Fc Silencing IgG1 Product Picture

Figure 15. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application (US$ Million), 2021–2032

Figure 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Application: 2025 & 2032

Figure 17. Bladder Cancer

Figure 18. Esophageal Cancer

Figure 19. Triple-negative Breast Cancer

Figure 20. Others

Figure 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size (US$ Million), 2021–2032

Figure 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), 2021–2032

Figure 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price (US$/Unit), 2021–2032

Figure 25. Nectin-4-Directed Antibody Drug Conjugates (ADC) Report Years Considered

Figure 26. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Share by Manufacturers in 2025

Figure 27. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Share by Manufacturers in 2025

Figure 28. Top 5 and Top 10 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Players: Market Share by Revenue in Nectin-4-Directed Antibody Drug Conjugates (ADC) in 2025

Figure 29. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 30. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 31. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)

Figure 32. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)

Figure 33. United States Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Canada Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)

Figure 36. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)

Figure 37. Germany Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. France Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. U.K. Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Italy Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Russia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021–2032)

Figure 43. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021–2032)

Figure 44. China Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. Japan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. South Korea Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. India Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Australia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. China Taiwan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Southeast Asia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)

Figure 52. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)

Figure 53. Mexico Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Brazil Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. Argentina Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Colombia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)

Figure 58. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)

Figure 59. Turkey Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Saudi Arabia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 61. UAE Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032

Figure 62. Global Sales Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type (2021–2032)

Figure 63. Global Revenue Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type (2021–2032)

Figure 64. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2021–2032)

Figure 65. Global Sales Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application (2021–2032)

Figure 66. Global Revenue Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application (2021–2032)

Figure 67. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2021–2032)

Figure 68. Nectin-4-Directed Antibody Drug Conjugates (ADC) Value Chain

Figure 69. Channels of Distribution (Direct Vs Distribution)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions